In a recent subgroup analysis of the DAPA-CKD trial, which focused on 270 patients with IgAN, dapagliflozin demonstrated a mean percentage difference of −35.0% in the urinary albumin-to-creatinine ratio (UACR) compared to placebo in the fourth month (5, 9). Here, ALB is linked to chronic kidney disease.